BRAF K601E-mutated metastatic colorectal cancer in response to combination therapy with encorafenib, binimetinib, and cetuximab: A case report

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

890

Figures (1-3)

127

Sum=1097

Publishing Process of This Article

Item

Count

Browse

Download

Sum=75

Jul 15, 2024 (publication date) through Nov 13, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastrointest Oncol. Jul 15, 2024; 16(7): 3357-3363
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.3357

Full Size Figure Download Figure

Figure 3 Schema of class II BRAF mutation and action of encorafenib, binimetinib, and cetuximab. This schema was created with BioRender.com.

Citation: Sasaki M, Shimura T, Nishie H, Kuroyanagi K, Kanno T, Fukusada S, Sugimura N, Mizuno Y, Nukui T, Uno K, Kojima Y, Nishigaki R, Tanaka M, Ozeki K, Kubota E, Kataoka H. BRAF K601E-mutated metastatic colorectal cancer in response to combination therapy with encorafenib, binimetinib, and cetuximab: A case report. World J Gastrointest Oncol 2024; 16(7): 3357-3363
URL: https://www.wjgnet.com/1948-5204/full/v16/i7/3357.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i7.3357